-
公开(公告)号：WO2010081817A1
公开(公告)日：2010-07-22
申请号：PCT/EP2010/050338
申请日：2010-01-13
Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH , LARSEN, Annette , BAUM, Anke , HILBERG, Frank , SOLCA, Flavio
Inventor： LARSEN, Annette , BAUM, Anke , HILBERG, Frank , SOLCA, Flavio
IPC: A61K31/496 , A61K31/517 , A61P35/00
CPC classification number: A61K31/496 , A61K31/517 , A61K2300/00
Abstract: The present invention relates to a method of treating patients suffering from colorectal cancer characterized by coadministration of BIBF 1120 and BIBW 2992, wherein in said method BIBF 1120 is administered according to a continuous daily regimen and BIBW 2992 is administered according to a weekly alternating on-off regimen, pharmaceutical compositions and kits suitable for this method as well as their preparation.
Abstract translation: 本发明涉及一种治疗患有结直肠癌患者的方法，其特征在于共同施用BIBF 1120和BIBW 2992，其中在所述方法中，BIBF 1120根据连续的每日方案给药，并且BIBW 2992根据每周交替 关闭方案，适用于该方法的药物组合物和试剂盒及其制备。
-
公开(公告)号：WO2007132010A1
公开(公告)日：2007-11-22
申请号：PCT/EP2007/054723
申请日：2007-05-15
Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH , ZAHN, Stephan Karl , BISTER, Bojan , BOEHMELT, Guido , GUERTLER, Ulrich , MANTOULIDIS, Andreas , REISER, Ulrich , SCHOOP, Andreas , SOLCA, Flavio , TONTSCH-GRUNT, Ulrike , TREU, Matthias
Inventor： ZAHN, Stephan Karl , BISTER, Bojan , BOEHMELT, Guido , GUERTLER, Ulrich , MANTOULIDIS, Andreas , REISER, Ulrich , SCHOOP, Andreas , SOLCA, Flavio , TONTSCH-GRUNT, Ulrike , TREU, Matthias
IPC: C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/14 , A61P35/00 , A61K31/506
CPC classification number: C07D405/12 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: Die vorliegende Erfindung umfasst Verbindungen der allgemeinen Formel (1) worin R 1 , R 2 , R 4 , R g , X, m, n und p wie in Anspruch 1 definiert sind, welche zur Behandlung von Krankheiten, die durch exzessive oder anomale Zellproliferation charakterisiert sind, geeignet sind, sowie deren Verwendung zur Herstellung eines Arzneimittels mit den vorstehend genannten Eigenschaften.
Abstract translation: 本发明包括通式（1）化合物，其中R 1 ，R 2 ，R 4 ，R 克，X，m，n和p如权利要求1中所定义，其适合于的疾病的特征在于过度或异常细胞增殖，以及它们对于具有上述特性的药物的制备中使用的治疗。
-
公开(公告)号：WO2007057397A1
公开(公告)日：2007-05-24
申请号：PCT/EP2006/068459
申请日：2006-11-14
Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , SOMMERGRUBER, Wolfgang , KRAUT, Norbert , SCHWEIFER, Norbert , RETTIG, Wolfgang , HILBERG, Frank , SOLCA, Flavio , STEEGMAIER, Martin
Inventor： SOMMERGRUBER, Wolfgang , KRAUT, Norbert , SCHWEIFER, Norbert , RETTIG, Wolfgang , HILBERG, Frank , SOLCA, Flavio , STEEGMAIER, Martin
IPC: A61K31/404 , A61K31/4045 , A61K31/454 , A61K31/4178 , A61K31/496 , A61P35/00
CPC classification number: A61K31/404 , A61K9/0031 , A61K9/02 , A61K9/1652 , A61K9/2077 , A61K31/4045 , A61K31/4178 , A61K31/454 , A61K31/496 , A61K47/02
Abstract: The invention is based on the finding that indolinones are useful for the therapy of diseases which result from aberrant activity of certain tyrosine kinases selected from the group comprising ABL, FGFR3, FLT3, and RET.
Abstract translation: 本发明基于这样的发现，即吲哚啉酮可用于治疗由选自ABL，FGFR3，FLT3和RET的组中的某些酪氨酸激酶的异常活性引起的疾病。
-
4.发明申请4- ( N-PHENYLAMINO ) -CHINAZOLINE/CHINOLINE ALS TYROSINKINASEINHIBITOREN 审中-公开4-（N-苯基氨基）-CHINAZOLINE /喹啉作为酪氨酸激酶抑制剂
公开(公告)号：WO2003082290A1
公开(公告)日：2003-10-09
申请号：PCT/EP2003/003062
申请日：2003-03-25
Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , HIMMELSBACH, Frank , JUNG, Birgit , SOLCA, Flavio
Inventor： HIMMELSBACH, Frank , JUNG, Birgit , SOLCA, Flavio
IPC: A61K31/517
CPC classification number: C07D401/12 , C07D239/94 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D491/08
Abstract: Die vorliegende Erfindung betrifft bicyclische Heterocyclen der allgemeinen Formel (I), in der R a , R b , R c , R d und X wie im Anspruch 1 definiert sind, deren Tautomere, deren Stereoisomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren, welche wertvolle pharmakologische Eigenschaften aufweisen, insbesondere eine Hemmwirkung auf die durch Tyrosinkinasen vermittelte Signaltransduktion, deren Verwendung zur Behandlung von Krankheiten, insbesondere von Tumorerkrankungen sowie der benignen Prostatahyperplasie (BPH), von Erkrankungen der Lunge und der Atemwege und deren Herstellung.
Abstract translation: 本发明涉及通式（I）的双环杂环，在其中R，R的，R
，R 和X如权利要求1，互变异构体，立体异构体，中所定义 混合物和它们的盐，特别是与具有有价值的药理性质上由酪氨酸激酶介导的无机酸或有机酸，特别是具有抑制效果及其生理学上可接受的盐的信号转导，其用于治疗疾病，特别是肿瘤疾病以及良性前列腺增生（BPH）的治疗使用中， 肺和呼吸道和其制备的疾病。 -
5.发明申请BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM 审中-公开双环杂环化合物，含有这些化合物的药物组合物，它们的用途和制备它们的方法
公开(公告)号：WO0055162A3
公开(公告)日：2000-12-28
申请号：PCT/EP0002229
申请日：2000-03-14
Applicant: BOEHRINGER INGELHEIM PHARMA , HIMMELSBACH FRANK , LANGKOPF ELKE , BLECH STEFAN , JUNG BIRGIT , METZ THOMAS , SOLCA FLAVIO
Inventor： HIMMELSBACH FRANK , LANGKOPF ELKE , BLECH STEFAN , JUNG BIRGIT , METZ THOMAS , SOLCA FLAVIO
IPC: A61K31/519 , A61K31/661 , A61P1/00 , A61P1/04 , A61P1/16 , A61P11/00 , A61P11/02 , A61P11/06 , A61P11/08 , A61P13/12 , A61P17/06 , A61P35/00 , A61P35/04 , A61P37/00 , C07D471/04 , C07D487/04 , A61K31/675 , C07F9/6561
CPC classification number: C07D471/04 , C07D487/04
Abstract: The present invention relates to bicyclic heterocyclic compounds of general formula (I) wherein Ra, Rb, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosinekinases, their use in treating diseases, particularly tumour diseases, diseases of the lung and airways and the preparation thereof.
Abstract translation: 本发明涉及通式（I）的双环杂环化合物，其中Ra，Rb，X和Y如权利要求1中所定义，其互变异构体，立体异构体和盐，特别是其与无机或有机酸或碱的生理学上可接受的盐 其具有有价值的药理学性质，特别是对由酪氨酸激酶介导的信号转导的抑制作用，它们在治疗疾病中的用途，特别是肿瘤疾病，肺和呼吸道疾病及其制备。
-
Patent Agency Ranking
公开(公告)号：WO2012095505A1
公开(公告)日：2012-07-19
申请号：PCT/EP2012/050466
申请日：2012-01-12
Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH , SOLCA, Flavio , GUERTLER, Ulrich , SANDERSON, Michael , TONTSCH-GRUNT, Ulrike , WAIZENEGGER, Irene
Inventor： SOLCA, Flavio , GUERTLER, Ulrich , SANDERSON, Michael , TONTSCH-GRUNT, Ulrike , WAIZENEGGER, Irene
IPC: A61K31/404 , A61K31/4045 , A61K31/506 , A61K45/06 , A61P35/00
CPC classification number: A61K31/496 , A61K9/0019 , A61K9/08 , A61K9/2018 , A61K9/2059 , A61K31/404 , A61K31/4045 , A61K31/506 , A61K45/06 , A61K2300/00
Abstract: The invention describes anti-cancer therapies comprising using dual Aurora kinase / MEK inhibitors as descibed herein.
Abstract translation: 本发明描述了包括使用如本文所述的双极光激酶/ MEK抑制剂的抗癌疗法。
-
7.发明申请
公开(公告)号：WO2011069962A1
公开(公告)日：2011-06-16
申请号：PCT/EP2010/068968
申请日：2010-12-06
Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH , HASLINGER, Christian , SOLCA, Flavio , UTTENREUTHER-FISCHER, Martina
Inventor： HASLINGER, Christian , SOLCA, Flavio , UTTENREUTHER-FISCHER, Martina
IPC: A61K31/337 , A61K31/517 , A61K31/675 , A61K31/704 , A61K33/24 , A61P35/00
CPC classification number: A61K31/517 , A61K31/337 , A61K31/675 , A61K31/704 , A61K33/24 , A61K2300/00
Abstract: The present invention relates to a method of treating patients suffering from triple negative breast cancer comprising administration of an effective amount of the irreversible EGFR/HER1 and HER2 inhibitor BIBW 2992 (1) to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent (2), in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery.
Abstract translation: 本发明涉及一种治疗患有三阴性乳腺癌的患者的方法，包括将有效量的不可逆EGFR / HER1和HER2抑制剂BIBW 2992（1）给予需要这种治疗的人，任选地与 通过外科手术与放射治疗，放射免疫治疗和/或肿瘤切除联合施用另外的化学治疗剂（2）。
-
8.发明申请2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER 审中-公开2- [（苯甲酰胺基） - 嘧啶-4-基]胺]羧酰胺衍生物及相关化合物作为细胞周期的细胞因子的抑制剂治疗癌症
公开(公告)号：WO2008077885A3
公开(公告)日：2008-08-14
申请号：PCT/EP2007064342
申请日：2007-12-20
Applicant: BOEHRINGER INGELHEIM INT , ZAHN STEPHAN , BOEHMELT GUIDO , GUERTLER ULRICH , MANTOULIDIS ANDREAS , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS
Inventor： ZAHN STEPHAN , BOEHMELT GUIDO , GUERTLER ULRICH , MANTOULIDIS ANDREAS , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS
IPC: C07D239/48 , A61K31/505 , A61P35/00
CPC classification number: C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14
Abstract: The present invention encompassescompounds of general formula (1) wherein R 1 to R 4 , X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised byexcessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
Abstract translation: 本发明包括通式（1）的化合物，其中R 1至R 4，X和n如权利要求1中所定义，其适用于治疗特征性疾病 过度或异常的细胞增殖，以及其用于制备具有上述性质的药物的用途。
-
公开(公告)号：WO2007054550A1
公开(公告)日：2007-05-18
申请号：PCT/EP2006/068313
申请日：2006-11-09
Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , SOLCA, Flavio , AMELSBERG, Andree , STEHLE, Gerd , VAN MEEL, Jacobus C.A. , BAUM, Anke
Inventor： SOLCA, Flavio , AMELSBERG, Andree , STEHLE, Gerd , VAN MEEL, Jacobus C.A. , BAUM, Anke
IPC: A61K31/517 , A61K31/553 , A61P35/00
CPC classification number: A61K31/517 , A61K31/553 , A61K33/24
Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
Abstract translation: 本发明涉及式（I）的喹唑啉的用途，其中基团R a至R d具有权利要求和说明书中给出的含义，在癌症治疗中 。
-
10.发明申请NOVEL 2-BENZYLAMINODIHYDROPTERIDINONES, METHOD FOR PRODUCING THEM AND USE THEREOF AS DRUGS 审中-公开新的2 BENZYLAMINODIHYDROPTERIDINONE，方法及其及其作为药物
公开(公告)号：WO2005123736A8
公开(公告)日：2006-03-30
申请号：PCT/EP2005006404
申请日：2005-06-15
Applicant: BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , HOFFMANN MATTHIAS , STEEGMAIER MARTIN , GRAUERT MATTHIAS , LEHMANN-LINTZ THORSTEN , REDEMANN NORBERT , SOLCA FLAVIO
Inventor： HOFFMANN MATTHIAS , STEEGMAIER MARTIN , GRAUERT MATTHIAS , LEHMANN-LINTZ THORSTEN , REDEMANN NORBERT , SOLCA FLAVIO
IPC: A61K31/519 , A61P35/00 , C07D475/00
CPC classification number: C07D475/00
Abstract: The invention relates to the novel 2-benzylaminodihydropteridinones of general formula (I), wherein the groups R
Abstract translation: 本发明涉及新的2- Benzylaminodihydropteridinone通式（I）其中基团R1至R7，R10和R11具有权利要求书和说明书中给出的含义，它们的异构体，制备这些二氢喋啶酮和作为药物中的用途的处理。
-
-
-
-
-
-
-
-
-
Search Results
35
records
(took 0.013 seconds)
